Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cell-mediated Immune Responses

Cell-mediated Immune Responses

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.

Haematologica·2026

Same author

Balancing the efficacy and safety of chimeric antigen receptor T-cell therapy by affinity combination.

Nature communications·2026

Same author

Quantifying HLA transcripts by genotype in chimeric mixtures at single-cell resolution.

bioRxiv : the preprint server for biology·2025

Same author

Impact of Gamma-Secretase Inhibition on Outcomes Following BCMA CAR-T Therapy in Multiple Myeloma: A Comparison of Two Phase 1 Trials.

Transplantation and cellular therapy·2025

Same author

A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-up.

Blood·2025

Same author

Design of sensitive monospecific and bispecific synthetic chimeric T cell receptors for cancer therapy.

Nature cancer·2025

Search research articles

Related Experiment Video

Updated: Jul 10, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Engineering antitumor immunity by T-cell adoptive immunotherapy.

Stanley R Riddell¹

¹Fred Hutchinson Cancer Res. Center, 1100 Fairview Ave. N, MS D3100, Seattle, WA 98109-4417, USA. sriddell@fhcrc.org

Hematology. American Society of Hematology. Education Program

|November 21, 2007

Summary

Adoptive T-cell therapy shows promise for B-cell lymphomas by engineering T cells for enhanced persistence and targeting. Advances in understanding T-cell properties improve efficacy for treating human malignancies.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8⁺ T Cells in Mice

Published on: June 12, 2021

Related Experiment Videos

Last Updated: Jul 10, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8⁺ T Cells in Mice

Published on: June 12, 2021

Area of Science:

Immunology
Oncology
Cell Therapy

Background:

Adoptive T-cell transfer is effective for viral infections and experimental tumors.
Treating human malignancies with T cells faces challenges in efficacy and persistence.
B-cell lymphomas are susceptible to T-cell-mediated eradication when specific antigens are presented.

Purpose of the Study:

To review advances in antigen-specific T-cell therapy for B-cell lymphomas.
To explore strategies for improving T-cell persistence and efficacy in vivo.
To discuss molecular engineering of T cells for targeting lymphoma.

Main Methods:

Review of current literature on T-cell therapy for B-cell lymphomas.
Analysis of T-cell properties essential for in vivo persistence and memory formation.
Examination of T-cell receptor engineering for targeting lymphoma-specific molecules.

Main Results:

Understanding T-cell properties enhances potential for long-term persistence and memory.
Molecular engineering of T cells offers new therapeutic strategies.
Successful T-cell therapy relies on antigen presentation and T-cell characteristics.

Conclusions:

Advances in T-cell biology and engineering are expanding therapeutic applications for B-cell lymphomas.
Improved understanding of T-cell persistence and targeting is key to enhancing efficacy.
T-cell therapy holds significant potential for treating human malignancies.